The trial studied the efficacy of bamlanivimab in combination with the antiviral remdesivir on Hospitalized Covid-19 patients. Researchers concluded the antibody treatment was "unlikely to help."
(Image credit: David Morrison/AP)
This post first appeared on NPR : National Public Radio : News & Analysis, Wor, please read the originial post: here